Literature DB >> 11590839

Pathobiology of pulmonary hypertension. Extracellular matrix.

M Rabinovitch1.   

Abstract

Changes in the extracellular matrix underlie the structural and functional abnormalities in the vessel wall that lead to progressive pulmonary vascular disease. Studies are reviewed aimed at addressing the cellular and molecular programs that regulate the production of the extracellular matrix describing new ways to arrest proliferation and migration of smooth muscle cells and to induce apoptosis. The latter can lead to the reversal of pathology at least in experimental animal models.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590839     DOI: 10.1016/s0272-5231(05)70282-3

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  35 in total

Review 1.  Novel approaches to pulmonary arterial hypertension drug discovery.

Authors:  Yon K Sung; Ke Yuan; Vinicio A de Jesus Perez
Journal:  Expert Opin Drug Discov       Date:  2016-02-27       Impact factor: 6.098

Review 2.  Pulmonary arterial hypertension: an imaging review comparing MR pulmonary angiography and perfusion with multidetector CT angiography.

Authors:  F P Junqueira; C M A O Lima; A C Coutinho; D B Parente; L K Bittencourt; L G P Bessa; R C Domingues; E Marchiori
Journal:  Br J Radiol       Date:  2012-08-29       Impact factor: 3.039

3.  ClC-3 chloride channel is upregulated by hypertrophy and inflammation in rat and canine pulmonary artery.

Authors:  Yan-Ping Dai; Shaner Bongalon; William J Hatton; Joseph R Hume; Ilia A Yamboliev
Journal:  Br J Pharmacol       Date:  2005-05       Impact factor: 8.739

Review 4.  Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.

Authors:  J L Wright; R D Levy; A Churg
Journal:  Thorax       Date:  2005-07       Impact factor: 9.139

5.  TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction.

Authors:  Natasha M Rogers; Maryam Sharifi-Sanjani; Mingyi Yao; Kedar Ghimire; Raquel Bienes-Martinez; Stephanie M Mutchler; Heather E Knupp; Jeffrey Baust; Enrico M Novelli; Mark Ross; Claudette St Croix; Johannes C Kutten; Caitlin A Czajka; John C Sembrat; Mauricio Rojas; David Labrousse-Arias; Timothy N Bachman; Rebecca R Vanderpool; Brian S Zuckerbraun; Hunter C Champion; Ana L Mora; Adam C Straub; Richard A Bilonick; Maria J Calzada; Jeffrey S Isenberg
Journal:  Cardiovasc Res       Date:  2016-10-13       Impact factor: 10.787

Review 6.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

7.  Superoxide dismutase mimetic, MnTE-2-PyP, attenuates chronic hypoxia-induced pulmonary hypertension, pulmonary vascular remodeling, and activation of the NALP3 inflammasome.

Authors:  Leah R Villegas; Dylan Kluck; Carlie Field; Rebecca E Oberley-Deegan; Crystal Woods; Michael E Yeager; Karim C El Kasmi; Rashmin C Savani; Russell P Bowler; Eva Nozik-Grayck
Journal:  Antioxid Redox Signal       Date:  2013-02-05       Impact factor: 8.401

8.  The superoxide dismutase mimetic, tempol, blunts right ventricular hypertrophy in chronic hypoxic rats.

Authors:  Britt Elmedal; Mette Y de Dam; Michael John Mulvany; Ulf Simonsen
Journal:  Br J Pharmacol       Date:  2003-12-01       Impact factor: 8.739

Review 9.  Pathogenic mechanisms of pulmonary arterial hypertension.

Authors:  Stephen Y Chan; Joseph Loscalzo
Journal:  J Mol Cell Cardiol       Date:  2007-09-20       Impact factor: 5.000

Review 10.  The Action of Smooth Muscle Cell Potassium Channels in the Pathology of Pulmonary Arterial Hypertension.

Authors:  Yasunobu Hayabuchi
Journal:  Pediatr Cardiol       Date:  2016-11-08       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.